Nasdaq · Healthcare
AtriCure, Inc. (ATRC)
As-reported financials and recent SEC filings for AtriCure, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$534.5M
Net income
$-11.4M
Net margin
-2.1%
Diluted EPS
$-0.24
ROE
-2.3%
P/E (TTM)
—
Market cap
$1.53B
Debt / equity
0.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $534.5M | $465.3M | $399.2M | $330.4M | $274.3M |
| Gross profit | $400.8M | $347.5M | $300.4M | $245.9M | $205.9M |
| Operating income | $-9.4M | $-40.0M | $-26.7M | $-42.7M | $55.2M |
| Net income | $-11.4M | $-44.7M | $-30.4M | $-46.5M | $50.2M |
| Diluted EPS | $-0.24 | $-0.95 | $-0.66 | $-1.02 | $1.09 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
SD2026-05-27
View on EDGAR →42026-05-22
View on EDGAR →42026-05-20
View on EDGAR →1442026-05-20
View on EDGAR →42026-05-20
View on EDGAR →42026-05-20
View on EDGAR →42026-05-20
View on EDGAR →42026-05-20
View on EDGAR →Go deeper on ATRC
Search AtriCure, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.